| Recruiting | A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Resectable HER2-positive Breast Cancer | Phase 3 | 2026-03-06 |
| Not Yet Recruiting | SYS6090 Combination Therapy in Advanced Lung Cancer Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | 2026-02-28 |
| Not Yet Recruiting | JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who H HER2-positive Colorectal Cancer | Phase 3 | 2026-02-06 |
| Recruiting | Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants Healthy Participants | Phase 1 | 2026-01-26 |
| Not Yet Recruiting | A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer HER2-positive Gastric Cancer | Phase 2 / Phase 3 | 2025-12-30 |
| Recruiting | Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma Unresectable Locally Advanced or Metastatic Melanoma | Phase 1 / Phase 2 | 2025-12-17 |
| Not Yet Recruiting | The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer Metastatic Colorectal Cancer (mCRC) | Phase 3 | 2025-10-01 |
| Recruiting | JMT106 Injection in the Treatment of Advanced Solid Tumors Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma | Phase 1 | 2025-09-25 |
| Recruiting | a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia Hypertriglyceridemia | Phase 1 / Phase 2 | 2025-09-09 |
| Not Yet Recruiting | A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy Primary Membranous Nephropathy | Phase 2 | 2025-06-30 |
| Not Yet Recruiting | JSKN003 Combined Treatment of HER2-positive Gastric Cancer HER2-positive Gastric Cancer | Phase 2 | 2025-06-15 |
| Recruiting | First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors Advanced Malignant Tumors | Phase 1 / Phase 2 | 2025-04-11 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-b Non-Small Cell Lung Cancer | Phase 3 | 2025-04-03 |
| Not Yet Recruiting | Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression | Phase 2 / Phase 3 | 2025-04-01 |
| Not Yet Recruiting | JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy | Phase 2 | 2025-04-01 |
| Recruiting | JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | Phase 3 | 2025-02-18 |
| Recruiting | A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Loca Early or Locally Advanced HER2-positive Breast Cancer | Phase 3 | 2024-12-16 |
| Recruiting | A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment fo Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC | Phase 3 | 2024-10-23 |
| Enrolling By Invitation | A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of J Healthy Subjects | Phase 1 | 2024-07-23 |
| Recruiting | A Study of JMT203 in Patients With Cancer Cachexia Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | 2024-05-15 |
| Not Yet Recruiting | Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lu Squamous Cell Non-small Cell Lung Cancer | Phase 2 / Phase 3 | 2024-05-01 |
| Not Yet Recruiting | JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or M Local Advanced or Metastatic NSCLC | Phase 3 | 2024-04-26 |
| Not Yet Recruiting | A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors | Phase 3 | 2024-04-05 |
| Unknown | A Study of JMT101 in Patients With Metastatic Colorectal Cancer Metastatic Colorectal Cancer (mCRC) | Phase 2 | 2024-01-01 |
| Recruiting | Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-posi First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer | Phase 3 | 2023-07-23 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone Giant Cell Tumor of Bone | Phase 3 | 2023-04-01 |
| Unknown | Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | — | 2022-09-01 |
| Unknown | Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis Glucocorticoid Induced Osteoporosis | Phase 2 | 2022-06-15 |
| Unknown | Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis Postmenopausal Osteoporosis | Phase 2 | 2022-04-21 |
| Recruiting | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line The Stomach Cancer | Phase 2 / Phase 3 | 2022-04-07 |
| Active Not Recruiting | JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation | Phase 2 | 2021-11-21 |
| Unknown | Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | Phase 2 | 2021-11-20 |
| Completed | A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone Giant Cell Tumor of Bone | — | 2021-11-10 |
| Recruiting | A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma B-cell Non Hodgkin Lymphoma | Phase 1 | 2021-10-12 |
| Completed | Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors Bone Metastases From Solid Tumors | Phase 1 | 2020-10-31 |
| Unknown | Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Can Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 1 | 2020-06-29 |
| Unknown | A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM Hypercalcemia of Malignancy | Phase 1 / Phase 2 | 2020-01-24 |
| Unknown | Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone Giant Cell Tumor of Bone | Phase 1 / Phase 2 | 2019-10-10 |
| Unknown | Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors Bone Metastases | Phase 1 | 2018-05-21 |
| Unknown | Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor Advanced Solid Tumor | Phase 1 | 2017-04-11 |